Clinical Study Data Request Registered Users, Please Login

Find by:

Study ID:
Medicine:
Phase:

A randomized, multicenter phase II study of the efficacy and safety of Trastuzumab-MCC-DM1 vs. Trastuzumab (Herceptin) and Docetaxel (Taxotere) in patients with metastatic HER2-positive breast cancer who have not received prior therapy for metastatic disease.
Trastuzumab Emtansine
BO21976
NCT00679341
malignant neoplasm of breast
Phase 2
 
January 2015

Powered by ideaPoint, Inc.